Manifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoPrevisione della comunità attualeNo 68.1%
Previsori
6
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 19 minuti fa
4 set 25, 22:10 UTC31 dic 29, 23:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
Will MDMA-assisted therapy for PTSD be approved by the FDA before 2030?
Manifold MarketsWill a vaccine for HIV be approved by the FDA by 2030?
Manifold MarketsWill a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Manifold MarketsBefore January 1st, 2030, will any treatment for celiac disease be approved by the FDA?
Manifold MarketsWhen will the FDA reclassify BPC-157 to Category 1?
KalshiEbola pandemic in 2026?
PolymarketRegole
Resolution criteria
- Resolve YES if, by 11:59:59 pm Eastern Time on December 31, 2029, the U.S. FDA grants any marketing authorization for human use (approval, licensure, De Novo grant, or 510(k) clearance) to a product that fits this definition: a living, multicellular construct assembled ex vivo from animal or human cells, engineered to perform autonomous tasks in vivo (e.g., locomotion/drug delivery)—i.e., a “xenobot/biobot/anthrobot”-type product.
- Verification must appear in one of the FDA’s public databases: Drugs@FDA (NDAs/BLAs), Purple Book (licensed biologics), PMA, De Novo, or 510(k).
- Links: Drugs@FDA, Purple Book, PMA, De Novo, 510(k).
- (fda.gov, accessdata.fda.gov)
- EUAs, INDs/IDEs, in vitro–only/research-use-only authorizations, animal-use approvals, or products consisting solely of dissociated cells or live microbes (e.g., standard cellular therapies or live biotherapeutics) do NOT count.